Response to antifibrotic therapy and decrease of circulating BAG3 protein levels in systemic sclerosis patients with reduced forced vital capacity - 27/04/24

Margot De Marco ^{a, b}, Anna Basile ^a, Anna Lisa Cammarota ^a, Claudia Iannone ^{c, d}, Antonia Falco ^a, Liberato Marzullo ^{a, b}, Alessandra Rosati ^{a, b}, Roberto Caporali ^{c, d}, Maria Caterina Turco ^{a, b, ⁎} , Nicoletta Del Papa ^{b, c, ⁎}

^a Department of Medicine, Surgery and Dentistry Schola Medica Salernitana, University of Salerno, Baronissi, Italy 

^b FIBROSYS s.r.l., Academic spin-off, University of Salerno, Baronissi, Italy 

^c Scleroderma Clinic, UOC Clinica Reumatologica, ASST Pini-CTO, Milano, Italy 

^d Department of Clinical Sciences and Community Health, University of Milan, Italy 

^⁎Corresponding author at: Department of Medicine, Surgery and Dentistry Schola Medica Salernitana, University of Salerno, Baronissi, Italy.Department of Medicine, Surgery and Dentistry Schola Medica Salernitana, University of SalernoBaronissiItaly^⁎⁎Corresponding author at: Scleroderma Clinic, UOC Clinica Reumatologica, ASST Pini-CTO, Milano, Italy.Scleroderma Clinic, UOC Clinica Reumatologica, ASST Pini-CTOMilanoItaly

Le texte complet de cet article est disponible en PDF.